LIVECAST Markets Briefs Calendar Search

Research

AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar Search AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive Account

Live News REGULATION FLASH L impact Sep 25, 2026, 02:22 PM UTC

EasyA Confidentially Submits Draft Registration Statement With SEC for Proposed Direct Listing

SquawkNews Newsroom

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

No ticker tags on this item.

Related stories

Utah Medical Products, Inc. Clarifies Tender Offer Expiration Date SALT LAKE CITY, UT / / September 25, 2026 / Utah Medical Products, Inc. NASDAQ:UTMD is offering to purchase up to 650,000 shares of its common stock at $75.00 per share. The condit L impact | REGULATION | Sep 25, 2026, 03:08 PM UTC US Treasury Sec. Bessent: US, Japan To Stay In Close Communication On Currency Markets, Via DBnews.com L impact | REGULATION | Sep 25, 2026, 02:56 PM UTC Pharming Announces US FDA Acceptance Of Snda For Lower Doses Of Joenja Pharming Group N.V. EURONEXT:PHARM L impact | REGULATION | Sep 25, 2026, 02:36 PM UTC Pharming Group N.V. (PHARM) Wins FDA Priority Review for Joenja sNDA in Younger Children FDA accepted Pharming’s sNDA for lower Joenja doses in children 4+ weighing 13—27 kg with APDS and granted Priority Review. PDUFA target action date is Jan 30, 2027.Material Detail L impact | REGULATION | Sep 25, 2026, 02:32 PM UTC Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS Leiden, the Netherlands, September 25, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today an L impact | REGULATION | Sep 25, 2026, 02:32 PM UTC Pharming wins FDA Priority Review for Joenja sNDA Pharming said the U.S. FDA accepted and granted Priority Review to its sNDA for lower doses of Joenja to treat children with APDS. L impact | REGULATION | Sep 25, 2026, 02:30 PM UTC

SQUAWK/NEWS

Live financial news for traders. Read the headline on screen or hear it through LiveCast while you stay on the trade.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

Product

Open LiveCast
Plans & Pricing
Institutional API
How LiveCast Works
Live Markets
Session Briefs
RSS Feed
Calendar
Search
Instrument directory

Research

Macro
Politics
Prediction Markets
AI Market Assistant
News Archive

For Traders

Market Movers
US Stocks
Why News Moves Markets
News for Traders
How to Trade the News
What Is an Audio Squawk?
Policy Calendar

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

Legal

Privacy Policy
Terms of Use

© 2026 SquawkNews SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.